PE20060937A1 - Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) - Google Patents
Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)Info
- Publication number
- PE20060937A1 PE20060937A1 PE2005001266A PE2005001266A PE20060937A1 PE 20060937 A1 PE20060937 A1 PE 20060937A1 PE 2005001266 A PE2005001266 A PE 2005001266A PE 2005001266 A PE2005001266 A PE 2005001266A PE 20060937 A1 PE20060937 A1 PE 20060937A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- agonists
- cannabinoid receptor
- sulfonylbenzimidazole
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE A ES UN ENLACE, C(Ra)2 EN DONDE Ra ES H, ALQUILO(C1-C4); B ES -C- O -N-; R1 ES ALQUILO(C1-C4) SUSTITUIDO; R2 ES ALQUILO(C3-C10), CICLOALQUILO, ALQUILO(C1-C2), ENTRE OTROS; R3 ES ARILO, CICLOALQUILO, ALQUILO(C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-(CICLOPROPILMETIL)-2-(2,2-DIMETILPROPIL)-5-(ISOPROPILSULFONIL)-1H-BENCIMIDAZOL, 1-(CICLOPROPILMETIL)-2-(2,2-DIMETILPROPIL)-5-(ETILSULFONIL)-1H-BENCIMIDAZOL, 1-(CICLOPROPILMETIL)-2-(2,2-DIMETILPROPIL)-5-[(TRIFLUOROMETIL)SULFONIL]-1H-BENCIMIDAZOL, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR CANNABINOIDE 2 (CB2) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES COMO NEURALGIAS, NEUROPATIAS, ARTRITIS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62457804P | 2004-11-02 | 2004-11-02 | |
US69635805P | 2005-06-30 | 2005-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060937A1 true PE20060937A1 (es) | 2006-10-19 |
Family
ID=35915103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005001266A PE20060937A1 (es) | 2004-11-02 | 2005-10-28 | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) |
Country Status (18)
Country | Link |
---|---|
US (1) | US7598393B2 (es) |
EP (1) | EP1809607B1 (es) |
JP (1) | JP2008518905A (es) |
AR (1) | AR053774A1 (es) |
AT (1) | ATE417830T1 (es) |
BR (1) | BRPI0517925A (es) |
CA (1) | CA2586179C (es) |
DE (1) | DE602005011844D1 (es) |
DO (1) | DOP2005000221A (es) |
ES (1) | ES2318556T3 (es) |
GT (1) | GT200500309A (es) |
MX (1) | MX2007005290A (es) |
NL (1) | NL1030324C2 (es) |
PA (1) | PA8651501A1 (es) |
PE (1) | PE20060937A1 (es) |
TW (1) | TW200621724A (es) |
UY (1) | UY29184A1 (es) |
WO (1) | WO2006048754A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
KR101269869B1 (ko) | 2004-09-24 | 2013-06-07 | 네오메드 인스티튜트 | 벤즈이미다졸 유도체, 그를 함유하는 조성물, 그의 제조방법 및 그의 용도 |
EP1960389B1 (en) * | 2005-09-30 | 2012-08-15 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
EP1937670A1 (en) * | 2005-09-30 | 2008-07-02 | Glaxo Group Limited | Benzimidazolones which have activity at m1 receptor |
WO2007036715A2 (en) * | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
EP1994011B1 (en) | 2006-03-06 | 2010-10-13 | RaQualia Pharma Inc | Sulfonyl benzimidazole derivatives |
TW200745049A (en) | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
SI2081572T1 (sl) * | 2006-07-04 | 2010-06-30 | Janssen Pharmaceutica Nv | Benzimidazolni kanabinoidni agonisti ki nosijo substituirano heterociklično skupino |
WO2008085302A1 (en) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
WO2008119694A1 (en) * | 2007-03-30 | 2008-10-09 | Janssen Pharmaceutica Nv | Benzimidazole cannabinoid agonists |
WO2009036297A1 (en) * | 2007-09-14 | 2009-03-19 | The Trustees Of The University Of Pennsylvania | Novel compounds for treatment of malignant tumors |
GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
CN101896471A (zh) * | 2007-12-17 | 2010-11-24 | 詹森药业有限公司 | 氟代烷基取代的苯并咪唑大麻素激动剂 |
CN102292328A (zh) * | 2009-01-22 | 2011-12-21 | 拉夸里亚创药株式会社 | 具有cb2受体激动活性的n-取代饱和杂环砜化合物 |
RU2636614C2 (ru) * | 2009-05-19 | 2017-11-24 | Вивия Байотек С.Л. | Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования |
US20110086853A1 (en) * | 2009-10-08 | 2011-04-14 | William Brown | Therapeutic Compounds |
MX2012005248A (es) | 2009-11-06 | 2012-06-14 | Univ Vanderbilt | Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica. |
CN105566182B (zh) * | 2016-02-24 | 2018-02-13 | 苏州天马精细化学品股份有限公司 | 一种2‑氨基‑4‑(乙磺酰基)苯酚的合成方法 |
GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
US10569189B1 (en) * | 2019-05-17 | 2020-02-25 | NextLeaf Solutions Ltd. | Method for acetylation of cannabinoids |
WO2022128050A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammation and pain |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1481049A (fr) * | 1965-11-25 | 1967-05-19 | France Ministre Des Armees | Nouveaux dialkylaminoalkyl-1 p-alkoxyphényl alkyl-2 benzimidazoles 5-substitués |
GB1198633A (en) | 1967-11-24 | 1970-07-15 | Ilford Ltd | Phenyl-Sulphonated Benzimidazoles |
US4177057A (en) * | 1977-10-25 | 1979-12-04 | United States Borax & Chemical Corporation | Herbicidal benzimidazoles |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
DE19507913C2 (de) * | 1995-03-07 | 1998-04-16 | Agfa Gevaert Ag | Farbfotografisches Silberhalogenidmaterial |
GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
JP3063162B2 (ja) * | 1995-12-28 | 2000-07-12 | 藤沢薬品工業株式会社 | ベンズイミダゾール誘導体 |
FR2751649B1 (fr) * | 1996-07-26 | 1998-08-28 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
EP1060166A1 (de) * | 1998-02-03 | 2000-12-20 | Boehringer Ingelheim Pharma KG | 5-gliedrige benzokondensierte heterocyclen als antithrombotika |
US6596772B1 (en) | 1999-08-27 | 2003-07-22 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
WO2001057020A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
US20070004713A1 (en) | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
TW593278B (en) | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
AR035235A1 (es) * | 2001-04-20 | 2004-05-05 | Wyeth Corp | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento |
SE0101387D0 (sv) * | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
US7199147B2 (en) * | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
SE0203070D0 (en) * | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
AU2004253543B2 (en) | 2003-07-01 | 2009-02-19 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
SE0302572D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0302570D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0302571D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
WO2006039243A1 (en) * | 2004-09-30 | 2006-04-13 | Janssen Pharmaceutica N.V. | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
WO2006039215A2 (en) * | 2004-09-30 | 2006-04-13 | Janssen Pharmaceutica N.V. | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
-
2005
- 2005-10-19 EP EP05800583A patent/EP1809607B1/en not_active Not-in-force
- 2005-10-19 AT AT05800583T patent/ATE417830T1/de not_active IP Right Cessation
- 2005-10-19 WO PCT/IB2005/003325 patent/WO2006048754A1/en active Application Filing
- 2005-10-19 CA CA2586179A patent/CA2586179C/en not_active Expired - Fee Related
- 2005-10-19 DE DE602005011844T patent/DE602005011844D1/de active Active
- 2005-10-19 JP JP2007538543A patent/JP2008518905A/ja active Pending
- 2005-10-19 MX MX2007005290A patent/MX2007005290A/es active IP Right Grant
- 2005-10-19 BR BRPI0517925-4A patent/BRPI0517925A/pt not_active IP Right Cessation
- 2005-10-19 ES ES05800583T patent/ES2318556T3/es active Active
- 2005-10-27 DO DO2005000221A patent/DOP2005000221A/es unknown
- 2005-10-28 PE PE2005001266A patent/PE20060937A1/es not_active Application Discontinuation
- 2005-10-28 GT GT200500309A patent/GT200500309A/es unknown
- 2005-10-31 UY UY29184A patent/UY29184A1/es not_active Application Discontinuation
- 2005-11-01 AR ARP050104571A patent/AR053774A1/es unknown
- 2005-11-01 TW TW094138221A patent/TW200621724A/zh unknown
- 2005-11-01 NL NL1030324A patent/NL1030324C2/nl not_active IP Right Cessation
- 2005-11-02 PA PA20058651501A patent/PA8651501A1/es unknown
- 2005-11-02 US US11/266,107 patent/US7598393B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1809607A1 (en) | 2007-07-25 |
CA2586179A1 (en) | 2006-05-11 |
NL1030324A1 (nl) | 2006-05-03 |
DOP2005000221A (es) | 2006-05-15 |
NL1030324C2 (nl) | 2006-11-27 |
JP2008518905A (ja) | 2008-06-05 |
GT200500309A (es) | 2006-09-11 |
US7598393B2 (en) | 2009-10-06 |
CA2586179C (en) | 2011-02-08 |
WO2006048754A1 (en) | 2006-05-11 |
PA8651501A1 (es) | 2006-06-02 |
EP1809607B1 (en) | 2008-12-17 |
US20060094750A1 (en) | 2006-05-04 |
ATE417830T1 (de) | 2009-01-15 |
TW200621724A (en) | 2006-07-01 |
DE602005011844D1 (de) | 2009-01-29 |
AR053774A1 (es) | 2007-05-23 |
UY29184A1 (es) | 2006-06-30 |
MX2007005290A (es) | 2007-07-09 |
ES2318556T3 (es) | 2009-05-01 |
BRPI0517925A (pt) | 2008-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
PE20140918A1 (es) | Compuestos de benzoxepina inhibidores de la pi3k | |
PE20070833A1 (es) | Compuestos de pirimidinil benzotiofeno | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
PE20080768A1 (es) | Compuestos de isoindolina 5-sustituidos | |
PE20120002A1 (es) | Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2 | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
PE20090328A1 (es) | Derivados de oxadiazol como moduladores de los receptores metabotropicos de glutamato | |
AR062111A1 (es) | Derivados de beta-d-glucopiranosil indol, metodo de preparacion, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
ECSP088511A (es) | Agonistas del receptor del neuropeptido-2 | |
PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20081882A1 (es) | Derivados de piridazinona utiles como inhibidores de glucano sintasa | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
CR9910A (es) | Antagonistas del receptor 3 de la histamina | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
PE20090511A1 (es) | Imidazopiridinonas | |
PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
PE20091425A1 (es) | Derivados de aminotiazol | |
PE20121047A1 (es) | Derivados de tiazolilpiperidina como fungicidas | |
AR066972A1 (es) | Derivados azapeptidicos | |
PE20081850A1 (es) | Derivados ciclizados como inhibidores de la eg-5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |